Despite several advances, 5-year survival in patients with head and neck squamous cell
carcinoma (HNSCC) remains unchanged at only 50%. The commonest cause of death is locally …

The unprecedented efficacy of chimeric antigen receptor (CAR) T-cell immunotherapy of
CD19 + B-cell malignancy has established a new therapeutic pillar of hematology–oncology. …

The immune system employs several checkpoint pathways to regulate responses, maintain
homeostasis and prevent self-reactivity and autoimmunity. Tumor cells can hijack these …

Background Cancer and transplant patients with COVID-19 have a higher risk of developing
severe and even fatal respiratory diseases, especially as they may be treated with immune-…

3046 Background: Recent FDA approvals make CAR T-cell therapy a clinical reality for
hematologic malignancy. Toxicity and antigen loss-mediated resistance remain problematic. …

Given the immune system's importance for cancer surveillance and treatment, we have
investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some …

Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients with
cancer is unknown. We aimed to assess the safety and immunogenicity of the BNT162b2 (…

There have been several reports noting anosmia and ageusia as possible symptoms of
COVID-19. This is of particular interest in oncology since patients receiving some cancer …

Cytotoxic T‐lymphocyte associated protein‐4 (CTLA‐4) and the Programmed Death Receptor
1 (PD‐1) are immune checkpoint molecules that are well‐established targets of antibody …

Health-care services are rapidly transforming their organization and workforce in response
to the coronavirus disease 2019 (COVID-19) pandemic. These changes, and a desire to …